Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV
Status:
Recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety and efficacy of lefitolimod and 3BNC117/10-1074
in HIV-1-infected individuals on ART and during ATI as intervention to reduce the HIV-1
reservoir
Phase:
Phase 2
Details
Lead Sponsor:
University of Aarhus
Collaborators:
Aalborg Universitetshospital Aalborg University Hospital Hvidovre University Hospital Odense University Hospital Oslo University Hospital Rigshospitalet, Denmark The Peter Doherty Institute for Infection and Immunity University of Utah